

해외 바이오의약품 임상 현황 (2019.12.3~2019.12.9)

한국바이오의약품협회, 2019.12.10.
출처: ClinicalTrials.gov

○ 미국 11건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03739801	MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma	Locally Advanced Unresectable Gastric Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma Metastatic Unresectable Gastric Adenocarcinoma Unresectable Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	Drug: Liposomal Irinotecan Other: Quality-of-Life Assessment Other: Questionnaire Administration Biological: Ramucirumab	University of Southern California National Cancer Institute (NCI) Ipse	Phase 1 Phase 2
NCT02846571	Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye	Diabetes	Biological: Human Pancreatic Islet Transplantation	Midhat H. Abdulreda Diabetes Research Institute Foundation Bascom Palmer Eye Institute University of Miami	Phase 1 Phase 2
NCT04190862	E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas	Anal Fistula	Drug: E-CEL UVEC	Weill Medical College of Cornell University Angiocrine Bioscience	Phase 1
NCT04188379	A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (an Autoimmune Disorder That Destroys Platelets, Blood Cells That Help With Clotting, and Can Lead to Easy or Excessive Bruising and Bleeding)	Primary Immune Thrombocytopenia	Biological: efgartigimod Other: Placebo	argenx BVBA	Phase 3
NCT04081389	Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer	Anatomic Stage 0 Breast Cancer AJCC v8 Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Early-Stage Breast Carcinoma Estrogen Receptor Negative HER2/Neu Negative Progesterone Receptor Negative Prognostic Stage 0 Breast Cancer AJCC v8 Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Triple-Negative Breast Carcinoma	Drug: Celecoxib Drug: Cyclophosphamide Drug: Doxorubicin Drug: Doxorubicin Hydrochloride Drug: Paclitaxel Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 1
NCT03867162	FY15-14: Tularemia Vaccine Protocol (NDBR Lot 4)	Tularemia	Biological: Live Attenuated Tularemia Vaccine	U.S. Army Medical Research and Development Command United States Army Medical Research Institute of Infectious Diseases	Phase 2
NCT03552796	sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer	Recurrent Bladder Carcinoma Bladder Cancer Stage 0 Bladder Cancer Stage I	Other: Pharmacokinetic Study Biological: Recombinant EphB4-HSA Fusion Protein	University of Southern California National Cancer Institute (NCI)	Phase 1
NCT04186871	Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis	Autoimmune Disorder Rheumatoid Arthritis Systemic Lupus Erythematosus Primary Sjögren's Syndrome	Drug: branebrutinib Drug: abatacept Drug: branebrutinib placebo	Bristol-Myers Squibb	Phase 2
NCT04184622	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight	Overweight Obesity	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 3
NCT04164888	Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy	Hypercholesterolemia	Drug: CIVI 007	Civi Biopharma, Inc.	Phase 2
NCT04158700	A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer	Advanced Cancer	Drug: LY3200882 Drug: Pembrolizumab	Eli Lilly and Company Merck Sharp & Dohme Corp.	Phase 1 Phase 2

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04186871	Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis	Autoimmune Disorder Rheumatoid Arthritis Systemic Lupus Erythematosus Primary Sjögren's Syndrome	Drug: branebrutinib Drug: abatacept Drug: branebrutinib placebo	Bristol-Myers Squibb	Phase 2

○ 프랑스 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04186871	Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis	Autoimmune Disorder Rheumatoid Arthritis Systemic Lupus Erythematosus Primary Sjögren's Syndrome	Drug: branebrutinib Drug: abatacept Drug: branebrutinib placebo	Bristol-Myers Squibb	Phase 2
NCT04158700	A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer	Advanced Cancer	Drug: LY3200882 Drug: Pembrolizumab	Eli Lilly and Company Merck Sharp & Dohme Corp.	Phase 1 Phase 2

해외 바이오의약품 임상 현황 (2019.12.3~2019.12.9)

한국바이오의약품협회, 2019.12.10.
출처: ClinicalTrials.gov

○ 독일 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03996473	Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases	Carcinoma, Non-Small-Cell Lung	Drug: Radium-223 dichloride (Xofigo, BAY 88-8223) Drug: Pembrolizumab	Bayer	Phase 1 Phase 2
NCT04186871	Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis	Autoimmune Disorder Rheumatoid Arthritis Systemic Lupus Erythematosus Primary Sjögren's Syndrome	Drug: branebrutinib Drug: abatacept Drug: branebrutinib placebo	Bristol-Myers Squibb	Phase 2

○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04184622	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight	Overweight Obesity	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 3

○ 중국 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04188860	Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy	Recurrent Cervical Carcinoma Persistent Advanced Cervical Carcinoma Chemotherapy Anti-PD-1 Antibody Immunotherapy	Drug: A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel	Lei Li Peking Union Medical College Hospital	Phase 2
NCT04137380	A Study of Mirikizumab in Healthy Chinese Participants	Healthy	Drug: Mirikizumab - IV Drug: Mirikizumab - SC Drug: Placebo - IV Drug: Placebo - SC	Eli Lilly and Company	Phase 1
NCT04184622	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight	Overweight Obesity	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 3